相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer
Hatem Soliman et al.
CLINICAL CANCER RESEARCH (2021)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
J. Cortes et al.
ANNALS OF ONCOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.
Li Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The tumor microenvironment (TME) and atezolizumab plus nab-paclitaxel (A plus nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Elisa Agostinetto et al.
CANCERS (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Ami N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld et al.
CANCER CELL (2020)
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
Matthew Kraman et al.
CLINICAL CANCER RESEARCH (2020)
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer
Hope S. Rugo et al.
FUTURE ONCOLOGY (2020)
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Wenting Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
D. Eiger et al.
ANNALS OF ONCOLOGY (2020)
ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
A. Bardia et al.
ANNALS OF ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li et al.
MOLECULAR CANCER (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Notch Signaling in Breast Cancer: A Role in Drug Resistance
McKenna BeLow et al.
CELLS (2020)
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study
Parisa Lotfinejad et al.
DIAGNOSTICS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
Sarah Sammons et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
SGNLVA-002: Single-arm, open label phase lb/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Hyo S. Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
Adam Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
Sandra M. M. Irenaeus et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Resistance to Antibody-Drug Conjugates
Sara Garcia-Alonso et al.
CANCER RESEARCH (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)
Rebecca Dent et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II
Francois P. Duhoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)
David A. Canton et al.
IMMUNOTHERAPY (2017)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Jung-Min Lee et al.
ONCOTARGET (2017)
LAG-3+tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+tumors
S. Burugu et al.
ANNALS OF ONCOLOGY (2017)
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer
Anton Safonov et al.
CANCER RESEARCH (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).
Carlos Alberto Gomez-Roca et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
A. K. Nowak et al.
ANNALS OF ONCOLOGY (2015)
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
Douglas B. Johnson et al.
IMMUNOTHERAPY (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
Ian Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Chrystelle Brignone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
Richard R. Furman et al.
LEUKEMIA & LYMPHOMA (2010)
Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches
Paola Rizzo et al.
CANCER RESEARCH (2008)
Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters
KM Taylor et al.
BIOCHEMICAL JOURNAL (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
分享论文
